title: Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma.
abstract: A 43-year-old woman with tubercular choroidal granuloma showed poor response to conventional first-line four-drug antitubercular therapy (ATT) and corticosteroids. A therapeutic trial with intravitreal bevacizumab (1.25 mg in 0.05 mL) injections as an adjunct to ATT and corticosteroids led to a prompt initial regression of granuloma with restoration of visual acuity that was sustained for almost 2 years. A subsequent recurrence of the same lesion with evidence of enhanced vascularity was treated with intravitreal bevacizumab alone, that led to a complete regression of the granuloma with no recurrence until 1 year of follow-up.
authors.affiliation: Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
authors.forename: Reema
authors.initials: R
authors.lastname: Bansal
authors.forename: Nikhil
authors.initials: N
authors.lastname: Beke
authors.forename: Aman
authors.initials: A
authors.lastname: Sharma
authors.forename: Amod
authors.initials: A
authors.lastname: Gupta
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant; D015862:Choroid Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D016896:Treatment Outcome; D014375:Tuberculoma / Q000188:drug therapy*; D014392:Tuberculosis, Ocular / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000995:Antitubercular Agents; D000068258:Bevacizumab